DCOY
Income statement / Annual
Last year (2024), Salarius Pharmaceuticals, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2024, Salarius Pharmaceuticals, Inc.'s net income was -$5.58 M.
See Salarius Pharmaceuticals, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$1.84 M |
$5.23 M |
$3.47 M |
$1.95 M |
$1.27 M |
$1.01 M |
$0.00 |
| Cost of Revenue |
$4.42 K
|
$10.05 K
|
$6.68 K
|
$19.18 K
|
$0.00
|
$0.00
|
$430.75 K
|
$506.53 K
|
$662.75 K
|
$49.88 K
|
| Gross Profit |
-$4.42 K
|
-$10.05 K
|
-$6.68 K
|
$1.82 M
|
$0.00
|
$0.00
|
$407.39 K
|
$767.97 K
|
$347.92 K
|
-$49.88 K
|
| Gross Profit Ratio |
0
|
0
|
0
|
0.99
|
0
|
0
|
0.21
|
0.6
|
0.34
|
0
|
| Research and Development Expenses |
$770.03 K
|
$7.17 M
|
$15.84 M
|
$8.55 M
|
$6.91 M
|
$4.02 M
|
$1.29 M
|
$16.99 M
|
$20.38 M
|
$12.75 M
|
| General & Administrative Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$4.96 M
|
$5.71 M
|
$7.13 M
|
$6.09 M
|
$6.09 M
|
$7.69 M
|
$2.33 M
|
$18.50 M
|
$19.86 M
|
$16.41 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$5.73 M
|
$12.88 M
|
$22.97 M
|
$14.63 M
|
$13.00 M
|
$11.71 M
|
$3.62 M
|
$35.49 M
|
$40.23 M
|
$29.16 M
|
| Cost And Expenses |
$5.73 M
|
$12.89 M
|
$22.98 M
|
$14.65 M
|
$13.02 M
|
$11.73 M
|
$3.64 M
|
$36.00 M
|
$40.90 M
|
$29.21 M
|
| Interest Income |
$158.54 K
|
$352.25 K
|
$218.73 K
|
$0.00
|
$0.00
|
$15.65 K
|
$14.99 K
|
$291.96 K
|
$393.11 K
|
$72.03 K
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$3.05 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$4.42 K
|
$10.05 K
|
$6.68 K
|
$19.18 K
|
$18.06 K
|
$16.93 K
|
$16.95 K
|
$324.55 K
|
$277.23 K
|
$49.88 K
|
| EBITDA |
-$5.57 M |
-$12.53 M |
-$31.60 M |
-$12.75 M |
-$7.33 M |
-$6.92 M |
-$1.65 M |
-$34.11 M |
-$39.22 M |
-$29.09 M |
| EBITDA Ratio |
0
|
0
|
0
|
-6.93
|
-1.4
|
-2
|
-0.85
|
-26.76
|
-38.8
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
-6.96
|
-1.49
|
-2.39
|
-0.86
|
-27.25
|
-39.47
|
0
|
| Total Other Income/Expenses Net |
$158.54 K
|
$352.25 K
|
-$8.63 M
|
$44.69 K
|
$434.09 K
|
$1.33 M
|
$14.99 K
|
$291.96 K
|
$393.11 K
|
$72.03 K
|
| Income Before Tax |
-$5.58 M
|
-$12.54 M
|
-$31.61 M
|
-$12.77 M
|
-$7.35 M
|
-$6.94 M
|
-$1.67 M
|
-$34.43 M
|
-$39.49 M
|
-$29.14 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
-6.94
|
-1.4
|
-2
|
-0.86
|
-27.02
|
-39.08
|
0
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Net Income |
-$5.58 M
|
-$12.54 M
|
-$31.61 M
|
-$12.77 M
|
-$7.35 M
|
-$6.94 M
|
-$1.67 M
|
-$34.43 M
|
-$39.49 M
|
-$29.14 M
|
| Net Income Ratio |
0
|
0
|
0
|
-6.94
|
-1.4
|
-2
|
-0.86
|
-27.02
|
-39.08
|
0
|
| EPS |
-86.92 |
-461.04 |
-1785.33 |
-926.01 |
-1415.85 |
-6366.21 |
-87374 |
-149250 |
-182250 |
-156000 |
| EPS Diluted |
-86.92 |
-461.04 |
-1785.33 |
-926.01 |
-1415.85 |
-6366.21 |
-87374 |
-149250 |
-182250 |
-156000 |
| Weighted Average Shares Out |
$64.15 K
|
$27.21 K
|
$17.70 K
|
$13.79 K
|
$5.19 K
|
$1.09 K
|
$20.53
|
$230.14
|
$216.45
|
$187.11
|
| Weighted Average Shares Out Diluted |
$64.15 K
|
$27.21 K
|
$17.70 K
|
$13.79 K
|
$5.19 K
|
$1.09 K
|
$20.53
|
$230.14
|
$216.45
|
$187.11
|
| Link |
|
|
|
|
|
|
|
|
|
|
